PCM
EVFM

Prelude Capital Management’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Prelude Capital Management’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-20
Closed -$1K – 2536
2020
Q2 		$1K Buy
+20
New +$1.35K ﹤0.01% 1903

Other funds holding EVFM

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Prelude Capital Management's EVFM Position: Q3 2020 in Review

Prelude Capital Management sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2020, closing a stake of 20 shares — an estimated $1K sold.

Prelude Capital Management first reported a position in EVFM in Q2 2020 and held it in 1 quarter. The position peaked at $1K in Q2 2020. 99 funds tracked by Wall St. Rank hold EVFM as of Q3 2020.

  • Prelude Capital Management reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Prelude Capital Management sold 20 Evofem Biosciences, Inc. Common Stock shares in Q3 2020, an estimated $1K.
  • Prelude Capital Management first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Prelude Capital Management's Evofem Biosciences, Inc. Common Stock position peaked at $1K in Q2 2020.
  • 99 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2020.

Based on Prelude Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.